Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

CLL patients: GIVe me three!

Marwan Kwok,Tatjana Stankovic

Blood（2023）

Cited 0|Views13
No score
Abstract
In this issue of Blood, Huber et al present a 3-year follow-up analysis of the phase 2 CLL2-GIVe trial, demonstrating continued robust clinical activity of the triplet combination of obinutuzumab, ibrutinib, and venetoclax in previ-ously untreated patients with del(17p) and/or TP53-mutated chronic lym-phocytic leukemia (CLL).
More
Translated text
Key words
patients,three!
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined